Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.
Martín M, González-Rivera M, Morales S, de la Haba-Rodriguez J, González-Cortijo L, Manso L, Albanell J, González-Martín A, González S, Arcusa A, de la Cruz-Merino L, Rojo F, Vidal M, Galván P, Aguirre E, Morales C, Ferree S, Pompilio K, Casas M, Caballero R, Goicoechea U, Carrasco E, Michalopoulos S, Hornberger J, Prat A. Martín M, et al. Among authors: ferree s. Curr Med Res Opin. 2015 Jun;31(6):1129-37. doi: 10.1185/03007995.2015.1037730. Epub 2015 Apr 23. Curr Med Res Opin. 2015. PMID: 25851308
Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.
Prat A, Galván P, Jimenez B, Buckingham W, Jeiranian HA, Schaper C, Vidal M, Álvarez M, Díaz S, Ellis C, Nuciforo P, Ferree S, Ribelles N, Adamo B, Ramón Y Cajal S, Peg V, Alba E. Prat A, et al. Among authors: ferree s. Clin Cancer Res. 2016 Feb 1;22(3):560-6. doi: 10.1158/1078-0432.CCR-15-0630. Epub 2015 Jul 7. Clin Cancer Res. 2016. PMID: 26152740 Free article.
Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer.
Lænkholm AV, Jensen MB, Eriksen JO, Roslind A, Buckingham W, Ferree S, Nielsen T, Ejlertsen B. Lænkholm AV, et al. Among authors: ferree s. Clin Breast Cancer. 2020 Aug;20(4):e423-e432. doi: 10.1016/j.clbc.2020.01.013. Epub 2020 Feb 4. Clin Breast Cancer. 2020. PMID: 32253134
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.
Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, Greil R, Dubsky P, Stoeger H, Rudas M, Jakesz R, Ferree S, Cowens JW, Nielsen T, Schaper C, Fesl C, Cuzick J. Gnant M, et al. Among authors: ferree s. Ann Oncol. 2015 Aug;26(8):1685-91. doi: 10.1093/annonc/mdv215. Epub 2015 May 1. Ann Oncol. 2015. PMID: 25935792 Free article.
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu S, Leung S, Geiss G, Snider J, Vickery T, Davies SR, Mardis ER, Gnant M, Sestak I, Ellis MJ, Perou CM, Bernard PS, Parker JS. Wallden B, et al. Among authors: ferree s. BMC Med Genomics. 2015 Aug 22;8:54. doi: 10.1186/s12920-015-0129-6. BMC Med Genomics. 2015. PMID: 26297356 Free PMC article.
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, Ferree S, Sgroi D, Schnabel C, Baehner FL, Mallon E, Dowsett M. Sestak I, et al. Among authors: ferree s. JAMA Oncol. 2018 Apr 1;4(4):545-553. doi: 10.1001/jamaoncol.2017.5524. JAMA Oncol. 2018. PMID: 29450494 Free PMC article. Clinical Trial.
PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
Fitzal F, Filipits M, Fesl C, Rudas M, Greil R, Balic M, Moinfar F, Herz W, Dubsky P, Bartsch R, Ferree S, Schaper C, Gnant M; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Fitzal F, et al. Among authors: ferree s. Br J Surg. 2021 Apr 5;108(3):308-314. doi: 10.1093/bjs/znaa089. Br J Surg. 2021. PMID: 33608712 Free PMC article. Clinical Trial.
58 results